Platelet activation: a promoter for psoriasis and its comorbidity, cardiovascular disease

Frontiers in Immunology

Immunology

Wenyan He¹  Ziqi Jiang¹  Aijun Chen¹  Xiaoran Jiang² 

[1] Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China;The First Clinical College, Chongqing Medical University, Chongqing, China;

关键词: platelet;    psoriasis;    cardiovascular disease;    leukocyte;    endothelial cell;    cytokines;   

DOI  :  10.3389/fimmu.2023.1238647

 received in 2023-06-12, accepted in 2023-07-31,  发布年份 2023

来源: Frontiers

【 摘 要 】

Psoriasis is a chronic inflammatory skin disease with a prevalence of 0.14% to 1.99%. The underlying pathology is mainly driven by the abnormal immune responses including activation of Th1, Th17, Th22 cells and secretion of cytokines. Patients with psoriasis are more likely to develop cardiovascular disease (CVD) which has been well recognized as a comorbidity of psoriasis. As mediators of hemostasis and thromboinflammation, platelets play an important part in CVD. However, less is known about their pathophysiological contribution to psoriasis and psoriasis-associated CVD. A comprehensive understanding of the role of platelet activation in psoriasis might pave the path for more accurate prediction of cardiovascular (CV) risk and provide new strategies for psoriasis management, which alleviates the increased CV burden associated with psoriasis. Here we review the available evidence about the biomarkers and mechanisms of platelet activation in psoriasis and the role of platelet activation in intriguing the common comorbidity, CVD. We further discussed the implications and efficacy of antiplatelet therapies in the treatment of psoriasis and prevention of psoriasis-associated CVD.

【 授权许可】

Unknown   
Copyright © 2023 Jiang, Jiang, Chen and He